

REFERENCES

1. Lee H, Lee IS, Choue R. Obesity, Inflammation and Diet. *Pediatric Gastroenterology, Hepatology & Nutrition*. 2013;16(3):143-52.
2. Moges B, Amare B, Fantahun B, Kassu A. High prevalence of overweight, obesity, and hypertension with increased risk to cardiovascular disorders among adults in northwest Ethiopia: a cross sectional study. *BMC Cardiovascular Disorders*. 2014;14.
3. Shields M. Overweight and obesity among children and youth. *Health reports*. 2006;17(3):27-42.
4. Jitnarin N, Kosulwat V, Rojroongwasinkul N, Boonpradern A, Haddock CK, Poston WS. Prevalence of overweight and obesity in Thai population: results of the National Thai Food Consumption Survey. *Eating and weight disorders : EWD*. 2011;16(4):e242-9.
5. Yamborisut U, Mo-Suwan L. Prevalence of childhood and adolescent obesity in Thailand: a review. *Journal of the Medical Association of Thailand = Chotmaihet thangphaet*. 2014;97(1):44-51.
6. Monteiro R, Azevedo I. Chronic Inflammation in Obesity and the Metabolic Syndrome. *Mediators of Inflammation*. 2010;2010.
7. Nishimura S, Manabe I, Nagai R. Adipose tissue inflammation in obesity and metabolic syndrome. *Discovery medicine*. 2009;8(41):55-60.
8. Tahergorabi Z, Khazaei M. The relationship between inflammatory markers, angiogenesis, and obesity. *ARYA Atherosclerosis*. 2013;9(4):247-53.
9. Fernández-Sánchez A, Madrigal-Santillán E, Bautista M, Esquivel-Soto J, Morales-González Á, Esquivel-Chirino C, et al. Inflammation, Oxidative Stress, and Obesity. *International Journal of Molecular Sciences*. 2011;12(5):3117-32.

10. Coussens LM, Werb Z. Inflammation and cancer. *Nature*. 2002;420(6917):860-7.
11. Rakoff-Nahoum S. Why Cancer and Inflammation? *The Yale Journal of Biology and Medicine*. 2006;79(3-4):123-30.
12. Vendramini-Costa DB, Carvalho JE. Molecular link mechanisms between inflammation and cancer. *Current pharmaceutical design*. 2012;18(26):3831-52.
13. Sweeney SE, Firestein GS. Rheumatoid arthritis: regulation of synovial inflammation. *The international journal of biochemistry & cell biology*. 2004;36(3):372-8.
14. Hurlimann D, Enseleit F, Ruschitzka F. [Rheumatoid arthritis, inflammation, and atherosclerosis]. *Herz*. 2004;29(8):760-8.
15. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. *The New England journal of medicine*. 2001;344(12):907-16.
16. Wong SH, Lord JM. Factors underlying chronic inflammation in rheumatoid arthritis. *Archivum immunologiae et therapiae experimentalis*. 2004;52(6):379-88.
17. Calder PC, Albers R, Antoine JM, Blum S, Bourdet-Sicard R, Ferns GA, et al. Inflammatory disease processes and interactions with nutrition. *The British journal of nutrition*. 2009;101 Suppl 1:S1-45.
18. Lucas SM, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. *British journal of pharmacology*. 2006;147 Suppl 1:S232-40.
19. Ingersoll MA, Platt AM, Potteaux S, Randolph GJ. Monocyte trafficking in acute and chronic inflammation. *Trends in immunology*. 2011;32(10):470-7.

20. Minihane AM, Vinoy S, Russell WR, Baka A, Roche HM, Tuohy KM, et al. Low-grade inflammation, diet composition and health: current research evidence and its translation. *The British journal of nutrition*. 2015;114(7):999-1012.
21. Smith CW. Endothelial adhesion molecules and their role in inflammation. *Canadian journal of physiology and pharmacology*. 1993;71(1):76-87.
22. Shaw JO. Leukocytes in chemotactic-fragment-induced lung inflammation. Vascular emigration and alveolar surface migration. *The American journal of pathology*. 1980;101(2):283-302.
23. Ley K. Molecular mechanisms of leukocyte recruitment in the inflammatory process. *Cardiovascular research*. 1996;32(4):733-42.
24. McDonald B, Kubes P. Cellular and molecular choreography of neutrophil recruitment to sites of sterile inflammation. *Journal of molecular medicine (Berlin, Germany)*. 2011;89(11):1079-88.
25. Ley K. The role of selectins in inflammation and disease. *Trends in molecular medicine*. 2003;9(6):263-8.
26. Romer LH, McLean NV, Yan HC, Daise M, Sun J, DeLisser HM. IFN-gamma and TNF-alpha induce redistribution of PECAM-1 (CD31) on human endothelial cells. *Journal of immunology (Baltimore, Md : 1950)*. 1995;154(12):6582-92.
27. Sanz MJ, Kubes P. Neutrophil-active chemokines in in vivo imaging of neutrophil trafficking. *European journal of immunology*. 2012;42(2):278-83.
28. Geronikaki AA, Gavalas AM. Antioxidants and inflammatory disease: synthetic and natural antioxidants with anti-inflammatory activity. *Combinatorial chemistry & high throughput screening*. 2006;9(6):425-42.

29. Cuzzocrea S. Role of nitric oxide and reactive oxygen species in arthritis. *Current pharmaceutical design*. 2006;12(27):3551-70.
30. Moller P, Danielsen PH, Karottki DG, Jantzen K, Roursgaard M, Klingberg H, et al. Oxidative stress and inflammation generated DNA damage by exposure to air pollution particles. *Mutation research Reviews in mutation research*. 2014;762:133-66.
31. Rosanna DP, Salvatore C. Reactive oxygen species, inflammation, and lung diseases. *Current pharmaceutical design*. 2012;18(26):3889-900.
32. Harris H. Role of chemotaxis in inflammation. *Physiological reviews*. 1954;34(3):529-62.
33. Wu TT, Chen TL, Chen RM. Lipopolysaccharide triggers macrophage activation of inflammatory cytokine expression, chemotaxis, phagocytosis, and oxidative ability via a toll-like receptor 4-dependent pathway: validated by RNA interference. *Toxicology letters*. 2009;191(2-3):195-202.
34. Feghali CA, Wright TM. Cytokines in acute and chronic inflammation. *Frontiers in bioscience : a journal and virtual library*. 1997;2:d12-26.
35. Samuelsson B. Arachidonic acid metabolism: role in inflammation. *Zeitschrift fur Rheumatologie*. 1991;50 Suppl 1:3-6.
36. Ricciotti E, FitzGerald GA. Prostaglandins and Inflammation. *Arteriosclerosis, thrombosis, and vascular biology*. 2011;31(5):986-1000.
37. Wenzel SE. Arachidonic acid metabolites: mediators of inflammation in asthma. *Pharmacotherapy*. 1997;17(1 Pt 2):3s-12s.
38. Sharma JN, Al-Omran A, Parvathy SS. Role of nitric oxide in inflammatory diseases. *Inflammopharmacology*. 2007;15(6):252-9.
39. Coleman JW. Nitric oxide in immunity and inflammation. *International immunopharmacology*. 2001;1(8):1397-406.

40. Guzik TJ, Korbut R, Adamek-Guzik T. Nitric oxide and superoxide in inflammation and immune regulation. *Journal of physiology and pharmacology : an official journal of the Polish Physiological Society*. 2003;54(4):469-87.
41. Conner EM, Grisham MB. Inflammation, free radicals, and antioxidants. *Nutrition (Burbank, Los Angeles County, Calif)*. 1996;12(4):274-7.
42. Closa D, Folch-Puy E. Oxygen free radicals and the systemic inflammatory response. *IUBMB life*. 2004;56(4):185-91.
43. Khansari N, Shakiba Y, Mahmoudi M. Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. *Recent patents on inflammation & allergy drug discovery*. 2009;3(1):73-80.
44. Griswold DE, Webb E, Schwartz L, Hanna N. Arachidonic acid-induced inflammation: inhibition by dual inhibitor of arachidonic acid metabolism, SK&F 86002. *Inflammation*. 1987;11(2):189-99.
45. Takayama K, Yuhki K, Ono K, Fujino T, Hara A, Yamada T, et al. Thromboxane A₂ and prostaglandin F₂α mediate inflammatory tachycardia. *Nature medicine*. 2005;11(5):562-6.
46. Stachowska E, Dolegowska B, Dziedziejko V, Rybicka M, Kaczmarczyk M, Bober J, et al. Prostaglandin E₂ (PGE₂) and thromboxane A₂ (TXA₂) synthesis is regulated by conjugated linoleic acids (CLA) in human macrophages. *Journal of physiology and pharmacology : an official journal of the Polish Physiological Society*. 2009;60(1):77-85.
47. Ohuchi K, Takahashi C, Watanabe M, Hirasawa N, Suzuki Y, Kudo M, et al. Metabolism of leukotriene C₄, D₄ and E₄ in allergic inflammation in rats. *Journal of clinical & laboratory immunology*. 1988;27(4):171-8.
48. Morelli JG, Yohn JJ, Lyons MB, Murphy RC, Norris DA. Leukotrienes C₄ and D₄ as potent mitogens for cultured human neonatal melanocytes. *The Journal of investigative dermatology*. 1989;93(6):719-22.

49. Crooks SW, Stockley RA. Leukotriene B4. The international journal of biochemistry & cell biology. 1998;30(2):173-8.
50. Di Gennaro A, Haeggstrom JZ. Targeting leukotriene B4 in inflammation. Expert opinion on therapeutic targets. 2014;18(1):79-93.
51. Stratton MS, Alberts DS. Current application of selective COX-2 inhibitors in cancer prevention and treatment. Oncology (Williston Park, NY). 2002;16(5 Suppl 4):37-51.
52. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. The Journal of rheumatology Supplement. 1997;49:15-9.
53. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Isakson P. Distribution of COX-1 and COX-2 in normal and inflamed tissues. Advances in experimental medicine and biology. 1997;400a:167-70.
54. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. Journal of neuropathology and experimental neurology. 2004;63(9):901-10.
55. Seibert K, Masferrer JL. Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor. 1994;4(1):17-23.
56. Zhang JM, An J. Cytokines, Inflammation and Pain. International anesthesiology clinics. 2007;45(2):27-37.
57. Klampfer L. Cytokines, inflammation and colon cancer. Current cancer drug targets. 2011;11(4):451-64.
58. Elenkov IJ, Iezzoni DG, Daly A, Harris AG, Chrousos GP. Cytokine dysregulation, inflammation and well-being. Neuroimmunomodulation. 2005;12(5):255-69.
59. Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest. 2000;117(4):1162-72.

60. Dinarello CA. Proinflammatory cytokines. *Chest*. 2000;118(2):503-8.
61. Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. *Nature clinical practice Rheumatology*. 2008;4(1):34-42.
62. Rothwell NJ. Functions and mechanisms of interleukin 1 in the brain. *Trends in pharmacological sciences*. 1991;12(11):430-6.
63. Beuscher HU, Colten HR. Structure and function of membrane IL-1. *Molecular immunology*. 1988;25(11):1189-99.
64. Schett G, Dayer JM, Manger B. Interleukin-1 function and role in rheumatic disease. *Nature reviews Rheumatology*. 2016;12(1):14-24.
65. Jager J, Gremeaux T, Gonzalez T, Bonnafous S, Debard C, Laville M, et al. Tpl2 kinase is upregulated in adipose tissue in obesity and may mediate interleukin-1beta and tumor necrosis factor- α effects on extracellular signal-regulated kinase activation and lipolysis. *Diabetes*. 2010;59(1):61-70.
66. Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. *Annals of the rheumatic diseases*. 2011;70 Suppl 1:i104-8.
67. Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? *Diabetes*. 2005;54 Suppl 2:S114-24.
68. Lu ZY, Bataille R, Poubelle P, Rapp MJ, Harousseau JL, Klein B. An interleukin 1 receptor antagonist blocks the IL-1-induced IL-6 paracrine production through a prostaglandin E2-related mechanism in multiple myeloma. *Stem cells (Dayton, Ohio)*. 1995;13 Suppl 2:28-34.
69. Turner M, Chantry D, Katsikis P, Berger A, Brennan FM, Feldmann M. Induction of the interleukin 1 receptor antagonist protein by transforming growth factor-beta. *European journal of immunology*. 1991;21(7):1635-9.

70. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. *Nature immunology*. 2015;16(5):448-57.
71. Maggio M, Guralnik JM, Longo DL, Ferrucci L. Interleukin-6 in aging and chronic disease: a magnificent pathway. *The journals of gerontology Series A, Biological sciences and medical sciences*. 2006;61(6):575-84.
72. Barnes TC, Anderson ME, Moots RJ. The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. *International journal of rheumatology*. 2011;2011:721608.
73. Gabay C. Interleukin-6 and chronic inflammation. *Arthritis research & therapy*. 2006;8 Suppl 2:S3.
74. Apostolaki M, Armaka M, Victoratos P, Kollias G. Cellular mechanisms of TNF function in models of inflammation and autoimmunity. *Current directions in autoimmunity*. 2010;11:1-26.
75. Sedger LM, McDermott MF. TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future. *Cytokine & growth factor reviews*. 2014;25(4):453-72.
76. Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF- α : structure, function and interaction with anti-TNF agents. *Rheumatology (Oxford, England)*. 2010;49(7):1215-28.
77. Watts AD, Hunt NH, Madigan MC, Chaudhri G. Soluble TNF-alpha receptors bind and neutralize over-expressed transmembrane TNF-alpha on macrophages, but do not inhibit its processing. *Journal of leukocyte biology*. 1999;66(6):1005-13.
78. Jinesh S. Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs. *Inflammopharmacology*. 2015;23(2-3):71-7.

79. Toussiot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an update. *Expert opinion on pharmacotherapy*. 2007;8(13):2089-107.
80. Toussiot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. *Expert opinion on pharmacotherapy*. 2004;5(3):581-94.
81. Heslinga SC, Van Sijl AM, De Boer K, Van Halm VP, Nurmohamed MT. Tumor necrosis factor blocking therapy and congestive heart failure in patients with inflammatory rheumatic disorders: a systematic review. *Current medicinal chemistry*. 2015;22(16):1892-902.
82. Esposito E, Cuzzocrea S. TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. *Current medicinal chemistry*. 2009;16(24):3152-67.
83. Altwegg R, Vincent T. TNF blocking therapies and immunomonitoring in patients with inflammatory bowel disease. *Mediators of Inflammation*. 2014;2014:172821.
84. Tobin AM, Kirby B. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. *BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy*. 2005;19(1):47-57.
85. McKellar GE, McCarey DW, Sattar N, McInnes IB. Role for TNF in atherosclerosis? Lessons from autoimmune disease. *Nature reviews Cardiology*. 2009;6(6):410-7.
86. Sbarsi I, Falcone C, Boiocchi C, Campo I, Zorzetto M, De Silvestri A, et al. Inflammation and atherosclerosis: the role of TNF and TNF receptors polymorphisms in coronary artery disease. *International journal of immunopathology and pharmacology*. 2007;20(1):145-54.
87. Tzanavari T, Giannogonas P, Karalis KP. TNF-alpha and obesity. *Current directions in autoimmunity*. 2010;11:145-56.

88. Illan-Gomez F, Gonzalvez-Ortega M, Orea-Soler I, Alcaraz-Tafalla MS, Aragon-Alonso A, Pascual-Diaz M, et al. Obesity and inflammation: change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. *Obesity surgery*. 2012;22(6):950-5.
89. Cawthorn WP, Sethi JK. TNF-alpha and adipocyte biology. *FEBS letters*. 2008;582(1):117-31.
90. Jung UJ, Choi MS. Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver Disease. *International Journal of Molecular Sciences*. 2014;15(4):6184-223.
91. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. *European cytokine network*. 2006;17(1):4-12.
92. Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. *Vitamins and hormones*. 2006;74:443-77.
93. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. *Trends in immunology*. 2004;25(1):4-7.
94. Moser B, Willmann K. Chemokines: role in inflammation and immune surveillance. *Annals of the rheumatic diseases*. 2004;63 Suppl 2:ii84-ii9.
95. Proost P, Wuyts A, van Damme J. The role of chemokines in inflammation. *International journal of clinical & laboratory research*. 1996;26(4):211-23.
96. Murdoch C, Finn A. Chemokine receptors and their role in inflammation and infectious diseases. *Blood*. 2000;95(10):3032-43.

97. Porasuphatana S, Tsai P, Rosen GM. The generation of free radicals by nitric oxide synthase. *Comparative biochemistry and physiology Toxicology & pharmacology : CBP*. 2003;134(3):281-9.
98. Murrell GA, Doland MM, Jang D, Szabo C, Warren RF, Hannafin JA. Nitric oxide: an important articular free radical. *The Journal of bone and joint surgery American volume*. 1996;78(2):265-74.
99. Blantz RC, Munger K. Role of nitric oxide in inflammatory conditions. *Nephron*. 2002;90(4):373-8.
100. Evans CH. Nitric oxide: what role does it play in inflammation and tissue destruction? *Agents and actions Supplements*. 1995;47:107-16.
101. Bloodsworth A, O'Donnell VB, Freeman BA. Nitric oxide regulation of free radical- and enzyme-mediated lipid and lipoprotein oxidation. *Arteriosclerosis, thrombosis, and vascular biology*. 2000;20(7):1707-15.
102. Hussain SP, He P, Subleski J, Hofseth LJ, Trivers GE, Mechanic L, et al. Nitric oxide is a key component in inflammation-accelerated tumorigenesis. *Cancer research*. 2008;68(17):7130-6.
103. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. *Physiological reviews*. 2007;87(1):315-424.
104. Trujillo M, Ferrer-Sueta G, Radi R. Peroxynitrite detoxification and its biologic implications. *Antioxidants & redox signaling*. 2008;10(9):1607-20.
105. Luiking YC, Engelen MP, Deutz NE. Regulation of nitric oxide production in health and disease. *Current opinion in clinical nutrition and metabolic care*. 2010;13(1):97-104.
106. Korhonen R, Lahti A, Kankaanranta H, Moilanen E. Nitric oxide production and signaling in inflammation. *Current drug targets Inflammation and allergy*. 2005;4(4):471-9.

107. Sakurai H, Kohsaka H, Liu MF, Higashiyama H, Hirata Y, Kanno K, et al. Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. *The Journal of clinical investigation*. 1995;96(5):2357-63.
108. van THRJ, Ralston SH. Nitric oxide and bone. *Immunology*. 2001;103(3):255-61.
109. Pham-Huy LA, He H, Pham-Huy C. Free Radicals, Antioxidants in Disease and Health. *International Journal of Biomedical Science : IJBS*. 2008;4(2):89-96.
110. Fang YZ, Yang S, Wu G. Free radicals, antioxidants, and nutrition. *Nutrition (Burbank, Los Angeles County, Calif)*. 2002;18(10):872-9.
111. Knight JA. Review: Free radicals, antioxidants, and the immune system. *Annals of clinical and laboratory science*. 2000;30(2):145-58.
112. Machlin LJ, Bendich A. Free radical tissue damage: protective role of antioxidant nutrients. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 1987;1(6):441-5.
113. Bala A, Chetia P, Dolai N, Khandelwal B, Haldar PK. Cat's whiskers flavonoid attenuated oxidative DNA damage and acute inflammation: its importance in lymphocytes of patients with rheumatoid arthritis. *Inflammopharmacology*. 2014;22(1):55-61.
114. Shazia Q, Mohammad ZH, Rahman T, Shekhar HU. Correlation of oxidative stress with serum trace element levels and antioxidant enzyme status in Beta thalassemia major patients: a review of the literature. *Anemia*. 2012;2012:270923.
115. Tuppo EE, Forman LJ. Free radical oxidative damage and Alzheimer's disease. *The Journal of the American Osteopathic Association*. 2001;101(12 Suppl Pt 1):S11-5.

116. Retz W, Gsell W, Munch G, Rosler M, Riederer P. Free radicals in Alzheimer's disease. *Journal of neural transmission Supplementum*. 1998;54:221-36.
117. Koutsilieri E, Scheller C, Grunblatt E, Nara K, Li J, Riederer P. Free radicals in Parkinson's disease. *Journal of neurology*. 2002;249 Suppl 2:ii1-5.
118. Maxwell SRJ. Free radicals and antioxidants in cardiovascular disease. 1997;44(4):307-17.
119. Prasad K, Kalra J. Oxygen free radicals and hypercholesterolemic atherosclerosis: effect of vitamin E. *American heart journal*. 1993;125(4):958-73.
120. Bankson DD, Kestin M, Rifai N. Role of free radicals in cancer and atherosclerosis. *Clinics in laboratory medicine*. 1993;13(2):463-80.
121. Mantovani G, Maccio A, Madeddu C, Mura L, Massa E, Gramignano G, et al. Reactive oxygen species, antioxidant mechanisms and serum cytokine levels in cancer patients: impact of an antioxidant treatment. *Journal of cellular and molecular medicine*. 2002;6(4):570-82.
122. Karihtala P, Soini Y. Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies. *APMIS : acta pathologica, microbiologica, et immunologica Scandinavica*. 2007;115(2):81-103.
123. Nunez-Cordoba JM, Martinez-Gonzalez MA. Antioxidant vitamins and cardiovascular disease. *Current topics in medicinal chemistry*. 2011;11(14):1861-9.
124. Padayatty SJ, Katz A, Wang Y, Eck P, Kwon O, Lee JH, et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. *Journal of the American College of Nutrition*. 2003;22(1):18-35.

125. Riccioni G, Bucciarelli T, Mancini B, Di Ilio C, Capra V, D'Orazio N. The role of the antioxidant vitamin supplementation in the prevention of cardiovascular diseases. *Expert opinion on investigational drugs*. 2007;16(1):25-32.
126. Sies H, Stahl W. Vitamins E and C, beta-carotene, and other carotenoids as antioxidants. *The American journal of clinical nutrition*. 1995;62(6 Suppl):1315s-21s.
127. Traber MG, Atkinson J. Vitamin E, antioxidant and nothing more. *Free radical biology & medicine*. 2007;43(1):4-15.
128. Giblin FJ. Glutathione: a vital lens antioxidant. *Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics*. 2000;16(2):121-35.
129. Paiva SA, Russell RM. Beta-carotene and other carotenoids as antioxidants. *Journal of the American College of Nutrition*. 1999;18(5):426-33.
130. Johnson EJ. The role of carotenoids in human health. *Nutrition in clinical care : an official publication of Tufts University*. 2002;5(2):56-65.
131. Pietta PG. Flavonoids as antioxidants. *Journal of natural products*. 2000;63(7):1035-42.
132. Rice-Evans C. Flavonoid antioxidants. *Current medicinal chemistry*. 2001;8(7):797-807.
133. Frei B. Reactive oxygen species and antioxidant vitamins: mechanisms of action. *The American journal of medicine*. 1994;97(3a):5S-13S; discussion 22S-8S.
134. Nikaido H. Molecular Basis of Bacterial Outer Membrane Permeability Revisited. *Microbiology and Molecular Biology Reviews*. 2003;67(4):593-656.

135. Raetz CRH, Whitfield C. Lipopolysaccharide Endotoxins. Annual review of biochemistry. 2002;71:635-700.
136. Caroff M, Karibian D, Cavaillon JM, Haefner-Cavaillon N. Structural and functional analyses of bacterial lipopolysaccharides. Microbes and infection / Institut Pasteur. 2002;4(9):915-26.
137. Zhang X, Morrison DC. Lipopolysaccharide structure-function relationship in activation versus reprogramming of mouse peritoneal macrophages. Journal of leukocyte biology. 1993;54(5):444-50.
138. Erridge C, Bennett-Guerrero E, Poxton IR. Structure and function of lipopolysaccharides. Microbes and infection / Institut Pasteur. 2002;4(8):837-51.
139. Brandenburg K, Wiese A. Endotoxins: relationships between structure, function, and activity. Current topics in medicinal chemistry. 2004;4(11):1127-46.
140. Goodman MG, Morrison DC, Weigle WO. Modulation of lipopolysaccharide (LPS)-mediated function by structural differences of two physically distinct fractions of Escherichia coli K235 LPS. Journal of immunology (Baltimore, Md : 1950). 1977;118(5):1852-7.
141. Alexander C, Rietschel ET. Bacterial lipopolysaccharides and innate immunity. Journal of endotoxin research. 2001;7(3):167-202.
142. Liang H, Hussey SE, Sanchez-Avila A, Tantiwong P, Musi N. Effect of lipopolysaccharide on inflammation and insulin action in human muscle. PloS one. 2013;8(5):e63983.
143. Hamesch K, Borkham-Kamphorst E, Strnad P, Weiskirchen R. Lipopolysaccharide-induced inflammatory liver injury in mice. Laboratory animals. 2015;49(1 Suppl):37-46.

144. Kim YH, Kim DH, Lim H, Baek DY, Shin HK, Kim JK. The anti-inflammatory effects of methylsulfonylmethane on lipopolysaccharide-induced inflammatory responses in murine macrophages. *Biological & pharmaceutical bulletin*. 2009;32(4):651-6.
145. Lorenz W, Buhrmann C, Mobasheri A, Lueders C, Shakibaei M. Bacterial lipopolysaccharides form procollagen-endotoxin complexes that trigger cartilage inflammation and degeneration: implications for the development of rheumatoid arthritis. *Arthritis research & therapy*. 2013;15(5):R111.
146. Salvemini D, Doyle TM, Cuzzocrea S. Superoxide, peroxynitrite and oxidative/nitrative stress in inflammation. *Biochemical Society transactions*. 2006;34(Pt 5):965-70.
147. Szabo C. The pathophysiological role of peroxynitrite in shock, inflammation, and ischemia-reperfusion injury. *Shock* (Augusta, Ga). 1996;6(2):79-88.
148. Allen JB, Keng T, Privalle C. Nitric oxide and peroxynitrite production in ocular inflammation. *Environmental health perspectives*. 1998;106 Suppl 5:1145-9.
149. Du Clos TW. Function of C-reactive protein. *Annals of medicine*. 2000;32(4):274-8.
150. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. *Nature reviews Immunology*. 2011;11(2):98-107.
151. Herder C, Carstensen M, Ouwers DM. Anti-inflammatory cytokines and risk of type 2 diabetes. *Diabetes, obesity & metabolism*. 2013;15 Suppl 3:39-50.
152. Trayhurn P. Hypoxia and adipose tissue function and dysfunction in obesity. *Physiological reviews*. 2013;93(1):1-21.

153. Lawler HM, Underkofler CM, Kern PA, Erickson C, Bredbeck B, Rasouli N. Adipose Tissue Hypoxia, Inflammation and Fibrosis in Obese Insulin Sensitive and Obese Insulin Resistant Subjects. *The Journal of clinical endocrinology and metabolism*. 2016;jc20154125.
154. O'Rourke RW, White AE, Metcalf MD, Olivas AS, Mitra P, Larison WG, et al. Hypoxia-induced inflammatory cytokine secretion in human adipose tissue stromovascular cells. *Diabetologia*. 2011;54(6):1480-90.
155. Snodgrass RG, Boss M, Zezina E, Weigert A, Dehne N, Fleming I, et al. Hypoxia Potentiates Palmitate-induced Pro-inflammatory Activation of Primary Human Macrophages. *The Journal of biological chemistry*. 2016;291(1):413-24.
156. Ye J. Emerging Role of Adipose Tissue Hypoxia in Obesity and Insulin Resistance. *International journal of obesity (2005)*. 2009;33(1):54-66.
157. Popa C, Netea MG, van Riel PL, van der Meer JW, Stalenhoef AF. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. *Journal of lipid research*. 2007;48(4):751-62.
158. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrúa C, Sanchez-Andrade A, Martin J, et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. *Clinical and experimental rheumatology*. 2006;24(1):83-6.
159. Miranda-Filloo JA, Llorca J, Carnero-Lopez B, Gonzalez-Juanatey C, Blanco R, Gonzalez-Gay MA. TNF-alpha antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients. *Clinical and experimental rheumatology*. 2012;30(6):850-5.
160. Nieto-Vazquez I, Fernández-Veledo S, de Alvaro C, Lorenzo M. Dual Role of Interleukin-6 in Regulating Insulin Sensitivity in Murine Skeletal Muscle. *Diabetes*. 2008;57(12):3211-21.

161. Dinarello CA, Simon A, van der Meer JWM. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. *Nature reviews Drug discovery*. 2012;11(8):633-52.
162. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses J, Seifert B, et al. [Interleukin-1 receptor antagonist-treatment of patients with type 2 diabetes]. *Ugeskrift for laeger*. 2007;169(45):3868-71.
163. Osborn O, Brownell S, Sanchez-Alavez M, Salomon D, Gram H, Bartfai T. Treatment with an Interleukin 1 beta antibody improves glycemic control in diet induced obesity. *Cytokine*. 2008;44(1):141-8.
164. Grzanna R, Lindmark L, Frondoza CG. Ginger--an herbal medicinal product with broad anti-inflammatory actions. *Journal of medicinal food*. 2005;8(2):125-32.
165. Hadjzadeh MAR, Ghanbari H, Keshavarzi Z, Tavakol-Afshari J. The Effects of Aqueous Extract of *Alpinia Galangal* on Gastric Cancer Cells (AGS) and L929 Cells in Vitro. *Iranian Journal of Cancer Prevention*. 2014;7(3):142-6.
166. Gancel AL, Ollitrault P, Froelicher Y, Tomi F, Jacquemond C, Luro F, et al. Leaf volatile compounds of six citrus somatic allotetraploid hybrids originating from various combinations of lime, lemon, citron, sweet orange, and grapefruit. *Journal of agricultural and food chemistry*. 2005;53(6):2224-30.
167. Dasgupta T, Rao AR, Yadava PK. Chemomodulatory efficacy of basil leaf (*Ocimum basilicum*) on drug metabolizing and antioxidant enzymes, and on carcinogen-induced skin and forestomach papillomagenesis. *Phytomedicine : international journal of phytotherapy and phytopharmacology*. 2004;11(2-3):139-51.

168. Boukhatem MN, Ferhat MA, Kameli A, Saidi F, Kebir HT. Lemon grass (*Cymbopogon citratus*) essential oil as a potent anti-inflammatory and antifungal drugs. *The Libyan journal of medicine*. 2014;9:25431.
169. Ramadan G, Al-Kahtani MA, El-Sayed WM. Anti-inflammatory and anti-oxidant properties of *Curcuma longa* (turmeric) versus *Zingiber officinale* (ginger) rhizomes in rat adjuvant-induced arthritis. *Inflammation*. 2011;34(4):291-301.
170. Gruenwald J, Freder J, Armbruster N. Cinnamon and health. *Critical reviews in food science and nutrition*. 2010;50(9):822-34.
171. Tuntipopipat S, Muangnoi C, Failla ML. Anti-inflammatory activities of extracts of Thai spices and herbs with lipopolysaccharide-activated RAW 264.7 murine macrophages. *Journal of medicinal food*. 2009;12(6):1213-20.
172. Schwabbauer ML. Use of the latent image technique to develop and evaluate problem-solving skills. *The American journal of medical technology*. 1975;41(12):457-62.
173. Siritwatanametanon N, Fiebich BL, Efferth T, Prieto JM, Heinrich M. Traditionally used Thai medicinal plants: in vitro anti-inflammatory, anticancer and antioxidant activities. *Journal of ethnopharmacology*. 2010;130(2):196-207.
174. Shao Q, Wang H, Guo H, Zhou A, Huang Y, Sun Y, et al. Effects of Shade Treatments on Photosynthetic Characteristics, Chloroplast Ultrastructure, and Physiology of *Anoectochilus roxburghii*. *PloS one*. 2014;9(2).
175. Du XM, Irino N, Furusho N, Hayashi J, Shoyama Y. Pharmacologically active compounds in the *Anoectochilus* and *Goodyera* species. *Journal of natural medicines*. 2008;62(2):132-48.
176. Zhang Y, Cai J, Ruan H, Pi H, Wu J. Antihyperglycemic activity of kinsenoside, a high yielding constituent from *Anoectochilus roxburghii* in

streptozotocin diabetic rats. Journal of ethnopharmacology. 2007;114(2):141-5.

177. Hsiao HB, Wu JB, Lin H, Lin WC. Kinsenoside isolated from *Anoectochilus formosanus* suppresses LPS-stimulated inflammatory reactions in macrophages and endotoxin shock in mice. Shock (Augusta, Ga). 2011;35(2):184-90.
178. Liu ZL, Liu Q, Xiao B, Zhou J, Zhang JG, Li Y. The vascular protective properties of kinsenoside isolated from *Anoectochilus roxburghii* under high glucose condition. Fitoterapia. 2013;86:163-70.
179. Cai J, Zhao L, Zhu E. A new flavonol triglycoside derived from *Anoectochilus elwesii* on stimulating glucose uptake in insulin-induced human HepG2 cells. Natural product research. 2015;29(15):1414-8.
180. Kim GN, Jang HD. Flavonol content in the water extract of the mulberry (*Morus alba* L.) leaf and their antioxidant capacities. Journal of food science. 2011;76(6):C869-73.
181. Subedi L, Timala S, Duwadi P, Thapa R, Paudel A, Parajuli K. Antioxidant activity and phenol and flavonoid contents of eight medicinal plants from Western Nepal. Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan / sponsored by All-China Association of Traditional Chinese Medicine, Academy of Traditional Chinese Medicine. 2014;34(5):584-90.
182. Cai Y, Sun M, Corke H. Antioxidant activity of betalains from plants of the amaranthaceae. Journal of agricultural and food chemistry. 2003;51(8):2288-94.
183. Kedare SB, Singh RP. Genesis and development of DPPH method of antioxidant assay. Journal of food science and technology. 2011;48(4):412-22.

184. Ebada SS, Edrada RA, Lin W, Proksch P. Methods for isolation, purification and structural elucidation of bioactive secondary metabolites from marine invertebrates. *Nature protocols*. 2008;3(12):1820-31.
185. Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. *Free radical biology & medicine*. 1999;26(9-10):1231-7.
186. Kumar J, Dhar P, Tayade AB, Gupta D, Chaurasia OP, Upreti DK, et al. Antioxidant capacities, phenolic profile and cytotoxic effects of saxicolous lichens from trans-Himalayan cold desert of Ladakh. *PloS one*. 2014;9(6):e98696.
187. Lü JM, Lin PH, Yao Q, Chen C. Chemical and molecular mechanisms of antioxidants: experimental approaches and model systems. *Journal of cellular and molecular medicine*. 2010;14(4):840-60.
188. Ngamwongsatit P, Banada PP, Panbangred W, Bhunia AK. WST-1-based cell cytotoxicity assay as a substitute for MTT-based assay for rapid detection of toxigenic *Bacillus* species using CHO cell line. *Journal of microbiological methods*. 2008;73(3):211-5.
189. Takamatsu N. [The new colorimetric assay (WST-1) for cellular growth with normal aging and Alzheimer's disease]. *Nihon Ronen Igakkai zasshi Japanese journal of geriatrics*. 1998;35(7):535-42.
190. Yin LM, Wei Y, Wang Y, Xu YD, Yang YQ. Long Term and Standard Incubations of WST-1 Reagent Reflect the Same Inhibitory Trend of Cell Viability in Rat Airway Smooth Muscle Cells. *International Journal of Medical Sciences*. 2013;10(1):68-72.
191. Tsikas D. Analysis of nitrite and nitrate in biological fluids by assays based on the Griess reaction: appraisal of the Griess reaction in the L-arginine/nitric oxide area of research. *Journal of chromatography B*,

Analytical technologies in the biomedical and life sciences. 2007;851(1-2):51-70.

192. Arya M, Shergill IS, Williamson M, Gommersall L, Arya N, Patel HR. Basic principles of real-time quantitative PCR. Expert review of molecular diagnostics. 2005;5(2):209-19.
193. Haddad F, Baldwin KM. Reverse transcription of the ribonucleic acid: the first step in RT-PCR assay. Methods in molecular biology (Clifton, NJ). 2010;630:261-70.
194. Nolan T, Hands RE, Bustin SA. Quantification of mRNA using real-time RT-PCR. Nature protocols. 2006;1(3):1559-82.
195. Navarro E, Serrano-Heras G, Castano MJ, Solera J. Real-time PCR detection chemistry. Clinica chimica acta; international journal of clinical chemistry. 2015;439:231-50.
196. Malinen E, Kassinen A, Rinttilä T, Palva A. Comparison of real-time PCR with SYBR Green I or 5'-nuclease assays and dot-blot hybridization with rDNA-targeted oligonucleotide probes in quantification of selected faecal bacteria. Microbiology (Reading, England). 2003;149(Pt 1):269-77.
197. The enzyme-linked immunosorbent assay (ELISA). Bulletin of the World Health Organization. 1976;54(2):129-39.
198. Kenny GE, Dunsmoor CL. Principles, problems, and strategies in the use of antigenic mixtures for the enzyme-linked immunosorbent assay. Journal of Clinical Microbiology. 1983;17(4):655-65.
199. Kim SH, Park MK, Kim JY, Chuong PD, Lee YS, Yoon BS, et al. Development of a sandwich ELISA for the detection of *Listeria* spp. using specific flagella antibodies. Journal of veterinary science. 2005;6(1):41-6.
200. Mahmood T, Yang PC. Western Blot: Technique, Theory, and Trouble Shooting. North American Journal of Medical Sciences. 2012;4(9):429-34.

201. Hirano S. Western blot analysis. *Methods in molecular biology* (Clifton, NJ). 2012;926:87-97.
202. Kurien BT, Scofield RH. Western blotting. *Methods* (San Diego, Calif). 2006;38(4):283-93.
203. Krauspe R, Scheer A. Coomassie brilliant blue G-250 dye-binding technique for determination of autolytic protein breakdown in *Euglena gracilis* and comparison to other methods of autolysis measurement. *Analytical biochemistry*. 1986;153(2):242-50.
204. Aminian M, Nabatchian F, Vaisi-Raygani A, Torabi M. Mechanism of Coomassie Brilliant Blue G-250 binding to cetyltrimethylammonium bromide: an interference with the Bradford assay. *Analytical biochemistry*. 2013;434(2):287-91.
205. Smith BJ. SDS Polyacrylamide Gel Electrophoresis of Proteins. *Methods in molecular biology* (Clifton, NJ). 1984;1:41-55.
206. Smith BJ. SDS polyacrylamide gel electrophoresis of proteins. *Methods in molecular biology* (Clifton, NJ). 1994;32:23-34.
207. Gibbons J. Western Blot: Protein Transfer Overview. *North American Journal of Medical Sciences*. 2014;6(3):158-9.
208. Kong LQ, Pu YH, Ma SK. [Better performance of Western blotting: quick vs slow protein transfer, blotting membranes and the visualization methods]. *Nan fang yi ke da xue xue bao = Journal of Southern Medical University*. 2008;28(1):26-9.
209. Serebriiskii IG, Mitina O, Pugacheva EN, Benevolenskaya E, Kotova E, Toby GG, et al. Detection of peptides, proteins, and drugs that selectively interact with protein targets. *Genome research*. 2002;12(11):1785-91.

210. Smejkal GB, Shainoff JR, Yakubenko AV. Direct chemiluminescent immunodetection of proteins in agarose gels. *Electrophoresis*. 2002;23(7-8):979-84.
211. Wilcox G. Insulin and Insulin Resistance. *Clinical Biochemist Reviews*. 2005;26(2):19-39.
212. Nordlie RC, Foster JD, Lange AJ. Regulation of glucose production by the liver. *Annual review of nutrition*. 1999;19:379-406.
213. Petersen KF, Shulman GI. Etiology of insulin resistance. *The American journal of medicine*. 2006;119(5 Suppl 1):S10-6.
214. Leahy JL. Pathogenesis of type 2 diabetes mellitus. *Archives of medical research*. 2005;36(3):197-209.
215. Blodgett AB, Kothinti RK, Kamyshko I, Petering DH, Kumar S, Tabatabai NM. A fluorescence method for measurement of glucose transport in kidney cells. *Diabetes Technology & Therapeutics*. 2011;13(7):743-51.
216. Chen Y, Zhang J, Zhang XY. 2-NBDG as a marker for detecting glucose uptake in reactive astrocytes exposed to oxygen-glucose deprivation in vitro. *Journal of molecular neuroscience : MN*. 2015;55(1):126-30.
217. Millon SR, Ostrander JH, Brown JQ, Raheja A, Seewaldt VL, Ramanujam N. Uptake of 2-NBDG as a method to monitor therapy response in breast cancer cell lines. *Breast cancer research and treatment*. 2011;126(1):55-62.
218. TeSlaa T, Teitell MA. Techniques to Monitor Glycolysis. *Methods in enzymology*. 2014;542:91-114.
219. Yoshioka K, Saito M, Oh KB, Nemoto Y, Matsuoka H, Natsume M, et al. Intracellular fate of 2-NBDG, a fluorescent probe for glucose uptake activity, in *Escherichia coli* cells. *Bioscience, biotechnology, and biochemistry*. 1996;60(11):1899-901.

220. Zou C, Wang Y, Shen Z. 2-NBDG as a fluorescent indicator for direct glucose uptake measurement. *Journal of biochemical and biophysical methods*. 2005;64(3):207-15.
221. Galland L. Diet and inflammation. *Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition*. 2010;25(6):634-40.
222. Cefalu WT. Inflammation, Insulin Resistance, and Type 2 Diabetes: Back to the Future? *Diabetes*. 2009;58(2):307-8.
223. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. *European heart journal*. 2008;29(24):2959-71.
224. Murakami A, Ohigashi H. Targeting NOX, INOS and COX-2 in inflammatory cells: chemoprevention using food phytochemicals. *International journal of cancer Journal international du cancer*. 2007;121(11):2357-63.
225. Frolov A, Yang L, Dong H, Hammock BD, Crofford LJ. Anti-inflammatory properties of prostaglandin E2: deletion of microsomal prostaglandin E synthase-1 exacerbates non-immune inflammatory arthritis in mice. *Prostaglandins, leukotrienes, and essential fatty acids*. 2013;89(5):351-8.
226. Lin CC, Huang PC, Lin JM. Antioxidant and hepatoprotective effects of *Anoectochilus formosanus* and *Gynostemma pentaphyllum*. *The American journal of Chinese medicine*. 2000;28(1):87-96.
227. Du XM, Sun NY, Irino N, Shoyama Y. Glycosidic constituents from in vitro *Anoectochilus formosanus*. *Chemical & pharmaceutical bulletin*. 2000;48(11):1803-4.
228. Feng D, Ling WH, Duan RD. Lycopene suppresses LPS-induced NO and IL-6 production by inhibiting the activation of ERK, p38MAPK, and NF-

kappaB in macrophages. *Inflammation research* : official journal of the European Histamine Research Society [et al]. 2010;59(2):115-21.

229. Kim HY, Hwang KW, Park SY. Extracts of *Actinidia arguta* stems inhibited LPS-induced inflammatory responses through nuclear factor-kappaB pathway in Raw 264.7 cells. *Nutrition research* (New York, NY). 2014;34(11):1008-16.
230. Castro JP, Ocampo YC, Franco LA. In vivo and in vitro anti-inflammatory activity of *Cryptostegia grandiflora* Roxb. ex R. Br. leaves. *Biological research*. 2014;47:32.
231. Wieser V, Moschen AR, Tilg H. Inflammation, cytokines and insulin resistance: a clinical perspective. *Archivum immunologiae et therapiae experimentalis*. 2013;61(2):119-25.
232. Borst SE. The role of TNF-alpha in insulin resistance. *Endocrine*. 2004;23(2-3):177-82.
233. Zhang JG, Liu Q, Liu ZL, Li L, Yi LT. Antihyperglycemic activity of *Anoectochilus roxburghii* polysaccharose in diabetic mice induced by high-fat diet and streptozotocin. *Journal of ethnopharmacology*. 2015;164:180-5.